Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Obseva SA OBSEF

Healthcare Biotechnology
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis and... see more

Recent & Breaking News (GREY:OBSEF)

ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain

GlobeNewswire March 22, 2022

ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update

GlobeNewswire March 10, 2022

ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix

GlobeNewswire February 10, 2022

ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

GlobeNewswire February 4, 2022

ObsEva Appoints Katja Buhrer as Chief Strategy Officer

GlobeNewswire February 1, 2022

ObsEva Announces Corporate Updates

GlobeNewswire January 28, 2022

ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain

GlobeNewswire January 6, 2022

ObsEva to Present at the H.C. Wainwright BioConnect 2022 Conference

GlobeNewswire January 3, 2022

ObsEva Added to the NASDAQ Biotechnology Index

GlobeNewswire December 20, 2021

ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

GlobeNewswire December 17, 2021

ObsEva Appoints Will Brown as Chief Financial Officer

GlobeNewswire December 13, 2021

ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021

GlobeNewswire December 10, 2021

ObsEva Announces Symposium and Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021

GlobeNewswire December 2, 2021

Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix

GlobeNewswire November 22, 2021

Obseva Announces Appointment of Stephanie Brown to its Board of Directors

GlobeNewswire November 22, 2021

Bolt Biotherapeutics Announces Changes to its Board of Directors

GlobeNewswire November 19, 2021

ObsEva Announces Third Quarter 2021 Financial Results and Business Update

GlobeNewswire November 4, 2021

ObsEva Announces Management Change

GlobeNewswire October 29, 2021

ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at ASRM 2021 Scientific Congress & Expo

GlobeNewswire October 20, 2021

ObsEva Announces Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at ASRM 2021 Scientific Congress & Expo

GlobeNewswire October 19, 2021